ArticleMolecular cancer therapeutics2011
p53R2 inhibits the proliferation of human cancer cells in association with cell-cycle arrest.
Article in Molecular cancer therapeutics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 46 citations in OpenAlex.
- A machine learning approach identifies cellular senescence on transcriptome data of human cells in vitro.GeroScience · 2025Article
- Ciprofloxacin-encapsulated solid lipid nanoparticles: a comprehensive biochemical analysis of cytotoxic effects, proliferation inhibition, and apoptotic induction in KG1-a leukemia cells.Medical oncology (Northwood, London, England) · 2025Article
- Prognostic value of RNA methylation-related genes in gastric adenocarcinoma based on bioinformatics.PeerJ · 2024Article
- Ribonucleotide reductase subunit switching in hepatoblastoma drug response and relapse.Communications biology · 2023Article
- Still no Rest for the Reductases: Ribonucleotide Reductase (RNR) Structure and Function: An Update.Sub-cellular biochemistry · 2022Review
- Sirtuin 4 Inhibits Prostate Cancer Progression and Metastasis by Modulating p21 Nuclear Translocation and Glutamate Dehydrogenase 1 ADP-Ribosylation.Journal of oncology · 2022Article
- δ-Catenin Participates in EGF/AKT/p21International journal of molecular sciences · 2021Article
- Integrative Analysis Reveals Across-Cancer Expression Patterns and Clinical Relevance of Ribonucleotide Reductase in Human Cancers.Frontiers in oncology · 2019Article
- miR-942 promotes proliferation and metastasis of hepatocellular carcinoma cells by inhibiting RRM2B.OncoTargets and therapy · 2019Article
- Synthesis andIranian journal of pharmaceutical research : IJPR · 2019Article
- Anticancer effect of S-allyl-L-cysteine via induction of apoptosis in human bladder cancer cells.Oncology letters · 2018Article
- Overexpression of p53R2 is associated with poor prognosis in lung sarcomatoid carcinoma.BMC cancer · 2017Article
- Transcriptome analysis of mammary epithelial cell gene expression reveals novel roles of the extracellular matrix.Biochemistry and biophysics reports · 2017Article
- PYCR1 and PYCR2 Interact and Collaborate with RRM2B to Protect Cells from Overt Oxidative Stress.Scientific reports · 2016Article
- Clofarabine Has Apoptotic Effect on T47D Breast Cancer Cell Line via P53R2 Gene Expression.Advanced pharmaceutical bulletin · 2015Article
- Flux balance analysis predicts essential genes in clear cell renal cell carcinoma metabolism.Scientific reports · 2015Article
- E2F1 regulates p53R2 gene expression in p53-deficient cells.Molecular and cellular biochemistry · 2015Article
- RRM2B-Mediated Regulation of Mitochondrial Activity and Inflammation under Oxidative Stress.Mediators of inflammation · 2015Article
- Tumor suppressor FOXO3 regulates ribonucleotide reductase subunit RRM2B and impacts on survival of cancer patients.Oncotarget · 2014Article
- Investigation of the association of hRRM1 and p53R2 gene polymorphisms in head and neck squamous cell carcinomas.Medical oncology (Northwood, London, England) · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
Abstract
Deregulation of the expression of p53R2, a p53-inducible homologue of the R2 subunit of ribonucleotide reductase, has been found in various human cancer tissues; however, the roles p53R2 plays in cancer progression and malignancy remain controversial. In the present study, we examined changes in gene expression profiles associated with p53R2 in cancer cells, using the analysis of cDNA microarray. Gene set enrichment analysis identified that the gene set regulating cell-cycle progression was significantly enriched in p53R2-silencing human oropharyngeal carcinoma KB cells. Attenuation of p53R2 expression significantly reduced p21 expression and moderately increased cyclin D1 expression in both wild-type p53 cancer cells (KB and MCF-7) and mutant p53 cancer cells (PC3 and MDA-MB-231). Conversely, overexpression of p53R2-GFP resulted in an increase in the expression of p21 and decrease in the expression of cyclin D1, which correlated with reduced cell population in S-phase in vitro and suppressed growth in vivo. Furthermore, the MAP/ERK kinase inhibitor PD98059 partially abolished modulation of p21 and cyclin D1 expression by p53R2. Moreover, under the conditions of nonstress and adriamycin-induced genotoxic stress, attenuation of p53R2 in KB cells significantly increased phosphorylated H2AX, which indicates that attenuation of p53R2 may enhance DNA damage induced by adriamycin. Overall, our study shows that p53R2 may suppress cancer cell proliferation partially by upregulation of p21 and downregulation of cyclin D1; p53R2 plays critical roles not only in DNA damage repair but also in proliferation of cancer cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.